Option chain shows key data for Eisai Co's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Eisai Co.

Eisai Co (OTC:ESALF) Stock, Option Chain

Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of a pharmaceutical business and other businesses. The pharmaceutical business is categorized by region, including Japan, Americas, China, Asia, and Europe, Middle East, and Africa. Eisai also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived by its Japanese pharmaceutical business, followed by its Americas pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.

Brain,Degenerative,Diseases,Parkinson,,Alzheimer,,Puzzle

Biotech

Large Cap

News

Health Care

General

BIIB

ESAIY

ESALF

The U.K.&#39;s Medicines and Healthcare products Regulatory Agency approved Eisai and Biogen&#39;s Leqembi for treating mild cognitive impairment and mild dementia due to Alzheimer&#39;s. Despite this, NICE stated the drug&#39;s benefits are too small to justify the cost for NHS use.

Biogen&#39;s Alzheimer&#39;s Drug Secures UK Approval, But An Independent Agency Does Not Recommend Reimbursement

medical-bottles-syringe-seen-biogen-logo-displayed-440nw-13618678a

Movers

ESALY

The European Medicines Agency&#39;s CHMP has rejected the approval of Eisai and Biogen&#39;s Alzheimer&#39;s treatment lecanemab, citing concerns over its risks. Eisai plans to appeal the decision and work towards making the treatment available in the EU, where Alzheimer&#39;s affects 6.9 million people.

Biogen/Eisai&#39;s Alzheimer&#39;s Drug Leqembi Gets &#39;No Go&#39; From European Drug Regulator&#39;s Advisory Panel, Cites Serious Side Events

Bernie Sanders

Politics

Bernie Sanders: &#39;Getting Sick In America Should Not Mean Going Bankrupt, Losing Your Home, Car, Or Life Savings&#39;

Eisai Co Ltd

Eli Lilly CEO told UK health secretary its Alzheimer's treatment could "prevent" disease: FT

Eli Lilly's Alzheimer's drug donanemab rejected for NHS use

Biogen slips as Morgan Stanley downgrades on Leqembi launch

Eisai reports HY results

Eisai Co., Ltd. 2025 Q2 - Results - Earnings Call Presentation

Eisai Co., Ltd. (ESALF) Q2 2025 Earnings Call Transcript

Eisai: Still Relatively Modest Market-Implied Expectations For Leqembi

Biogen gains as Eisai wins EU nod for Alzheimer's drug

Eisai wins orphan drug status for Lenvima for esophageal cancer

Merck: Seriously Undervalued At Peak Pessimism (Rating Upgrade)

ABBV

AMGN

AZNCF

BMYMP

BRCTF

GLAXF

NONOF

NVSEF

REGN

SPGI

Eisai Co

Comments

Eisai Co

Eisai Co (ESALF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga